NVCHI
PTCT icon

New Vernon Capital Holdings II’s PTC Therapeutics PTCT Stock Holding History

New Vernon Capital Holdings II’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$250K Hold
3,668
– – 0.18% 33
2025
Q4 		$279K Sell
3,668
-7
-0.2% -$509 0.13% 39
2025
Q3 		$226K Buy
+3,675
New +$191K 0.1% 53

Other funds holding PTCT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

New Vernon Capital Holdings II's PTCT Position: Q1 2026 in Review

New Vernon Capital Holdings II held its PTC Therapeutics (PTCT) position steady in Q1 2026 at 3,668 shares worth $250K. The position accounts for 0.18% of the portfolio, ranked #33.

New Vernon Capital Holdings II first reported a position in PTCT in Q3 2025 and has held it in 3 quarters since. The position peaked at $279K in Q4 2025. 350 funds tracked by Wall St. Rank hold PTCT as of Q1 2026.

  • New Vernon Capital Holdings II held 3,668 shares of PTC Therapeutics worth $250K as of Q1 2026.
  • New Vernon Capital Holdings II left its PTC Therapeutics share count unchanged in Q1 2026.
  • PTC Therapeutics made up 0.18% of New Vernon Capital Holdings II's portfolio in Q1 2026, its #33 holding.
  • New Vernon Capital Holdings II first reported a position in PTC Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • New Vernon Capital Holdings II's PTC Therapeutics position peaked at $279K in Q4 2025.
  • 350 funds tracked by Wall St. Rank held PTC Therapeutics as of Q1 2026.

Based on New Vernon Capital Holdings II's 13F filing for Q1 2026, filed 15 May 2026.